FR23C1025I2 - Méthodes de traitement de syndromes lymphoprolifératifs associés au virus d'epstein-barr à l'aide d'une thérapie par cellules t - Google Patents

Méthodes de traitement de syndromes lymphoprolifératifs associés au virus d'epstein-barr à l'aide d'une thérapie par cellules t

Info

Publication number
FR23C1025I2
FR23C1025I2 FR23C1025C FR23C1025C FR23C1025I2 FR 23C1025 I2 FR23C1025 I2 FR 23C1025I2 FR 23C1025 C FR23C1025 C FR 23C1025C FR 23C1025 C FR23C1025 C FR 23C1025C FR 23C1025 I2 FR23C1025 I2 FR 23C1025I2
Authority
FR
France
Prior art keywords
methods
cell therapy
barr virus
associated lymphoproliferative
lymphoproliferative syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1025C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center Undefined
Original Assignee
Memorial Sloan Kettering Cancer Center Undefined
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56027234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1025(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center Undefined filed Critical Memorial Sloan Kettering Cancer Center Undefined
Publication of FR23C1025I1 publication Critical patent/FR23C1025I1/fr
Application granted granted Critical
Publication of FR23C1025I2 publication Critical patent/FR23C1025I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR23C1025C 2015-05-12 2023-06-14 Méthodes de traitement de syndromes lymphoprolifératifs associés au virus d'epstein-barr à l'aide d'une thérapie par cellules t Active FR23C1025I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562160549P 2015-05-12 2015-05-12
PCT/US2016/031784 WO2016183153A1 (en) 2015-05-12 2016-05-11 Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Publications (2)

Publication Number Publication Date
FR23C1025I1 FR23C1025I1 (fr) 2023-07-21
FR23C1025I2 true FR23C1025I2 (fr) 2025-04-18

Family

ID=56027234

Family Applications (1)

Application Number Title Priority Date Filing Date
FR23C1025C Active FR23C1025I2 (fr) 2015-05-12 2023-06-14 Méthodes de traitement de syndromes lymphoprolifératifs associés au virus d'epstein-barr à l'aide d'une thérapie par cellules t

Country Status (18)

Country Link
US (1) US10568908B2 (OSRAM)
EP (1) EP3294304B1 (OSRAM)
JP (2) JP7284556B2 (OSRAM)
KR (1) KR102666781B1 (OSRAM)
CN (1) CN107835690A (OSRAM)
AR (1) AR104598A1 (OSRAM)
AU (1) AU2016262484B2 (OSRAM)
BR (1) BR112017024431B1 (OSRAM)
CA (1) CA2984178C (OSRAM)
CL (1) CL2017002846A1 (OSRAM)
FR (1) FR23C1025I2 (OSRAM)
IL (1) IL255581B (OSRAM)
MX (1) MX386334B (OSRAM)
NZ (1) NZ736675A (OSRAM)
PH (1) PH12017501993A1 (OSRAM)
RU (1) RU2720245C2 (OSRAM)
WO (1) WO2016183153A1 (OSRAM)
ZA (1) ZA201707335B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017203356A1 (en) 2016-05-25 2017-11-30 The Council Of The Queensland Institute Of Medical Research Methods of immunotherapy
JP7002769B2 (ja) * 2016-09-16 2022-02-04 ベイラー カレッジ オブ メディスン ウイルス特異的ｔ細胞の活性化および拡大のためのプラットフォーム
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
CN108220237B (zh) * 2017-12-20 2020-11-06 中国科学院遗传与发育生物学研究所 一种人的nk/t细胞系
US20200350049A1 (en) * 2018-01-08 2020-11-05 Atara Biotherapeutics, Inc. Systems and methods for distributing cell therapies
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
KR20220092905A (ko) * 2019-10-23 2022-07-04 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 입양 면역요법
CN118256604B (zh) * 2024-04-16 2024-11-19 华中科技大学 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
RU2506311C2 (ru) 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
US20140086888A1 (en) 2010-09-01 2014-03-27 Helen E. Heslop Ebv-specific cytotoxic t-lymphocytes for the treatment of locoregional nasopharyngeal carcinoma (npc)
BR112014027957A8 (pt) * 2012-05-08 2018-01-16 Univ Johns Hopkins métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer"
CA2889064A1 (en) * 2012-10-19 2014-04-24 The Council Of The Queensland Institute Of Medical Research Improved human herpesvirus immunotherapy
CN105848484A (zh) * 2013-10-25 2016-08-10 得克萨斯州大学系统董事会 用于免疫治疗的多克隆γδ T细胞
TWI673365B (zh) * 2014-11-05 2019-10-01 美國紀念斯隆 凱特琳癌症中心 選擇用於過繼性細胞療法之ｔ細胞株及其供體之方法
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Also Published As

Publication number Publication date
CA2984178A1 (en) 2016-11-17
KR102666781B1 (ko) 2024-05-20
US10568908B2 (en) 2020-02-25
AR104598A1 (es) 2017-08-02
BR112017024431A2 (pt) 2018-07-24
RU2017143151A (ru) 2019-06-13
EP3294304A1 (en) 2018-03-21
AU2016262484B2 (en) 2021-10-21
MX386334B (es) 2025-03-18
CA2984178C (en) 2023-10-31
RU2017143151A3 (OSRAM) 2019-10-29
JP7284556B2 (ja) 2023-05-31
CN107835690A (zh) 2018-03-23
AU2016262484A1 (en) 2018-01-04
IL255581B (en) 2021-03-25
ZA201707335B (en) 2021-02-24
RU2720245C2 (ru) 2020-04-28
PH12017501993A1 (en) 2018-03-26
HK1244697A1 (en) 2018-08-17
CL2017002846A1 (es) 2018-05-25
FR23C1025I1 (fr) 2023-07-21
KR20180003575A (ko) 2018-01-09
US20180125891A1 (en) 2018-05-10
NZ736675A (en) 2023-03-31
JP2018520095A (ja) 2018-07-26
MX2017014257A (es) 2018-04-20
EP3294304B1 (en) 2020-01-29
BR112017024431B1 (pt) 2021-10-13
WO2016183153A1 (en) 2016-11-17
IL255581A (en) 2018-01-31
JP2021119154A (ja) 2021-08-12

Similar Documents

Publication Publication Date Title
FR23C1025I1 (fr) Méthodes de traitement de syndromes lymphoprolifératifs associés au virus d'epstein-barr à l'aide d'une thérapie par cellules t
HUS2200053I1 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
PL3684377T3 (pl) Sposoby leczenia zakażenia wirusem zapalenia wątroby typu b
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
EP3340971A4 (en) METHOD FOR TREATING LENNOX-GASTAUT SYNDROME WITH FENFLURAMINE
MA40867A (fr) Méthodes pour le traitement d'infections virales à filoviridae
PL3346995T3 (pl) Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
EP3442996A4 (en) TREATMENT PROCEDURE WITH CHLOROTOXIN CONJUGATES
EP3512524A4 (en) METHOD AND COMPOSITIONS FOR TREATING VIRUS INFECTIONS
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
EP3370723A4 (en) TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
EP3317290A4 (en) COMPOSITIONS AND METHOD FOR TREATING VIRUS INFECTION
LT3137078T (lt) Virusinio hepatito delta infekcijos gydymas
MA43925A (fr) Procã‰dã‰s de traitement du virus de l'hã‰patite b
EP3463406A4 (en) COMPOSITIONS AND METHODS FOR TREATING LYTICS AND LYSOGENIC VIRUSES
EP3355691A4 (en) Mollusk-killing biopesticide
EP3322805A4 (en) PURIFICATION OF NUCLEIC ACIDS USING COPPER TITANIUM OXIDES
ZA201804025B (en) Inactivation of viruses by delipidation
LT3360580T (lt) Genetinio gydymo būdas, naudojant aav-xbp1s/gfp virusą ir jo panaudojimas amiotrofinės šoninės sklerozės prevencijai ir gydymui
EP3958858A4 (en) METHODS OF TREATMENT AGAINST VIRUSES
EP3393524A4 (en) PROTECTION OF RNAS FROM DEGRADATION BY MEANS OF VIRUS RNAS
IL288713A (en) Methods for treating viral infections
EP3261439A4 (en) METHOD AND MATERIALS FOR TREATING HUMAN IMMUNE WEAKAGE VIRUS INFECTIONS
PL3710025T3 (pl) Biomasa sinic do zastosowania w leczeniu zakażenia wirusem zapalenia wątroby typu b